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Abstract
Objectives. The object of our study was to report on the experience with vascular resections at pancreatectomy in
two European specialist hepatopancreatobiliary centres and evaluate outcome and prognostic factors. Patients and
methods. From 1989 to 2002, 45 patients (21 men, 24 women) underwent pancreatectomy for a pancreatic mass: Whipple’s
procedure (n/33), total pancreatectomy (n/10) or left splenopancreatectomy (n/2), along with a vascular resection,
i.e. venous (n/39), arterial (n/1) or venous/arterial (n/5). Results. Operative mortality was nil, postoperative mortality
was 2.2% (n/1); 34 patients had an uneventful postoperative course. Reoperations were performed for portal vein
thromobosis (n/1), pancreatic leak (n/1), gastric outlet syndrome (n/1) and gastrointestinal bleeding (n/1). In all,
43 patients had cancer on pathology examination, with retropancreatic invasion in 72% and lymph node extension in
62.8%. Resection was R0 in 21 cases. Vessel wall invasion was present in 13 cases and 19 had perivascular invasion. Disease-
free survival (DFS) at 1, 2 and 3 years was 36.0%, 15.0% and 12.0%, respectively. Median DFS length was 8.7 months
(95% CI: 7.2; 10.2). Overall survival rates were 56.6%, 28.9% and 19.2%, respectively. Median survival length was
14.2 months (95% CI: 9.8; 18.6). A multivariate analysis of prognostic variables identified tumour location (other than
head of pancreas), neoadjuvant chemotherapy and advanced disease stage as adverse factors for DFS. Conclusion. Survival
and DFS rates of these patients are comparable to those without vascular resection. Tumour localization, tumour stage,
neoadjuvant treatment and tumour recurrence are explanatory variables of survival. Tumour localization, tumour stage and
neoadjuvant treatment were explanatory variables for DFS. However, the type and extent of vascular resections as well as
vessel wall invasion does not affect survival and DFS.
Introduction
Vascular resection during pancreatectomy for pan-
creatic cancer is still debated. Although the first cases
were reported in the early 1970s [1], the reports by
Fortner introduced the concept of regional pancrea-
tectomy with vascular resection, describing type I and
II where venous or arterial segment were resected,
respectively [24].
Recent reports from expert centres showed clearly
that vascular resection did not increase morbidity and
mortality, and can offer these patients the possibility
of radical surgery [58]. Nonetheless, the presence of
vascular invasion on preoperative staging is still
considered by many as a contraindication for surgery.
In this study, we report the experience with vascular
resection at pancreatectomy in two European specia-
list hepatopancreatobiliary centres and evaluate out-
come and prognostic factors.
Patients and methods
From May 1989 to March 2002, 45 patients (21 men,
24 women; mean age 609/13 years, range 26
82), underwent pancreatectomy for a pancreatic
mass, along with a vascular resection. Cases were
reviewed from two centres where a total of 756
pancreatectomies were performed. Patients with
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vascular resection represented 16.5% of the pancrea-
tectomies carried out. There was no difference
between them regarding main clinical and demo-
graphic characteristics. The main clinical presenta-
tions were: jaundice in 30 cases, abdominal pain in
25, alteration of general condition and weight loss in
20 and pruritis in 15. Other less frequent manifesta-
tions were vomiting in seven patients, diarrhoea in
five, diabetes in four, constipation in three, chronic
pancreatitis in two, acute pancreatitis in one, cholan-
gitis in one, dysphagia in one, flushing and sweating in
one and abdominal mass in one. All patients received
radiological and/or endoscopic exploration (US/29,
CT scan/37, angio-MRI/2, arteriography/15,
ERCP or percutaneous transhepatic cholangio-pan-
creatography (PTCP)/20, US-endoscopy/4) that
revealed the presence of a pancreatic mass. Tumour
localization was pancreatic head in 34 patients
(2 extending to the uncinate process), pancreatic
neck in 1 and body in 5, duodenum in 1, bile duct
in 2, ampullary tumour in 1 and right colon tumour
extending to the pancreatic head in 1. The mean
tumour size on radiological examination9/SD was
obtained in only 21 cases at 2.79/3.1 cm (range
213 cm).
In 20 cases, tumour was considered to be limited to
the pancreas, in the other 25 cases tumour was
invading adjacent structures  vascular invasion in
23 cases (venous invasion was observed in 16, arterial
invasion in 1 and combined venous and arterial in 6).
These patients presented with venous smooth shift in
four cases, unilateral narrowing in three, bilateral
narrowing in six and thrombosis with collateral
circulation in nine according to the Ishikawa classifi-
cation [9]. Retropancreatic invasion was seen in five
patients, duodenum in two, bile duct in one and colon
in one.
Biliary drainage was performed in 20 cases 
through an endoscopic stent in 13 patients, percuta-
neous transhepatic radiological drain in 5, nasobiliary
drain in 1 and surgical cholecysto-jejunostomy in 1.
None had distant metastasis recognized before sur-
gery.
Preoperative cytological examination of the pan-
creatic mass was carried out in 16 cases; 8 had
adenocarcinoma, 4 had neuroendocrine-type tumour
and in 4 no malignancy was identified. Neoadjuvant
chemotherapy was administered to five patients with
pancreatic adenocarcinoma.
Surgical resections were as follows: Whipple
procedure in 33 cases (1 was associated with right
colectomy, 15 with pylorus preservation), total pan-
createctomy in 10 (8 with associated splenectomy
and 2 with pylorus preservation) and left spleno-
pancreatectomy in 2. Pancreatic anastomosis was
done through pancreatico-jejunostomy in 32 patients
and pancreatico-gastrostomy in 1. Gastro-jejunostomy
was performed in 28 patients and pylorus preservation
in 17 (37.8%). Hepatico-jejunostomy was performed
in 43 patients.
Vascular resections were preoperatively pro-
grammed and intentionally performed according to
the results of preoperative investigations in 24 cases
(1 had associated peroperative vascular injury). In the
other 21 cases vascular resection was not preopera-
tively programmed but was done in 20 cases because
of severe adhesions between the pancreatic mass and
blood vessels (with associated vascular injury in 4),
and in 1 case it was done because of peroperative
vascular injury without obvious adhesions between
tumour and blood vessels. Venous resections were
partial circumference in 17 cases and full circumfer-
ence in 23, and 3 patients had combined partial
and full circumference resection. The mean length of
venous resection was 0.989/1.29 cm (range 14 cm).
Venous reconstruction included 17 direct veno-
venous anastomoses, 19 lateral venous repairs and
8 veno-venous homografts.
Arterial resection was carried out in six patients. All
were preoperatively programmed arterial vascular
resections, confirmed during surgery because of
severe adhesions between the tumour mass and the
arterial wall; 4 were associated with venous resection
and two were isolated arterial resections. All except
one arterial resection were full circumferential that
included one replaced right hepatic artery (RRHA)/
superior mesenteric artery (SMA), one RRHA, one
SMA, one proper hepatic artery (PHA)/splenic
artery (SA), one common hepatic artery (CHA) and
one SA.
Two patients had repair with cryopreserved arterial
allograft, one had autologous venous graft, one had
lateral suture repair, one had direct anastomosis and
one with no repair (SA resection).
.
Statistical analysis
The statistical unit was the patient. Descriptive
statistics were based on percentage for categorical
data and on mean9/SD for continuous variables. The
entire population was analysed, then only the subset
of cancer patients was considered for clinical, biolo-
gical and morphological analysis to identify factors
affecting prognosis.
Survival and disease-free survival (DFS) analysis
was performed according to the KaplanMeier tech-
nique from the date of surgery to that of death or
event (DFS) or to the most recent clinic visit.
Univariate survival analysis was performed to select
potential explanatory variables. According to the type
of data, comparisons were based on univariate Cox
regression model. Multivariate models were built
using Cox proportional hazards survival analysis
regression model in three ways (i.e. forwards,
backwards and manually). Risk factors related to
baseline hazards (odds) function for the sample were
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examined. The choice of the best explanatory model
was made by assessment of the goodness of fit, with an
entry level of 0.25 and removal level of 0.15. All
analyses were performed with SPSS software (10.0 for
Windows; SPSS Inc., Chicago, IL, USA).
Results
There was no operative mortality, one patient died in
the postoperative course secondary to acute pancrea-
titis and fistula, with a 30-day hospital mortality of
2.2%. The postoperative course was uneventful in
34 cases, medical complications were observed in
6 (infection, pleural effusion, diabetes)  all were
controlled successfully. All patients were followed for
anastomotic leak; pancreatic leak was defined by the
presence of leak on radiology control for pancreatico-
gastric anastomosis or by the presence of raised
amylase level in drainage fluid (5/serum level)
[10]. Surgical complications were observed in five
cases: associated pancreatic and biliary leak in one
(which was successfully treated conservatively),
one pancreatic leak with acute pancreatitis was re-
operated for completion pancreatectomy (the patient
died postoperatively), one patient had upper gastro-
intestinal bleeding requiring surgical exploration
which revealed haemorrhage secondary to haemobilia
that was successfully treated, one patient had gastric
outlet syndrome (gastric distention with absence of
gastric emptying on postoperative radiology control)
requiring gastro-jejunostomy redo with good out-
come, and one vascular complication occurred after
portal/superior mesenteric vein resection with direct
anastomosis; on day one he developed ascites and
echo-Doppler examination revealed anastomotic
thrombosis. The patient was re-operated and success-
fully received an autologous venous graft harvested
from the superficial femoral vein at mid-thigh.
Pathological examination revealed chronic pancrea-
titis in 2 cases and malignancy in 43: 36 (75.6%) with
pancreatic adenocarcinoma, of which 34 were of
ductal type (of which there was 1 microglandular
adenocarcinoma, 4 infiltrating and 1 squamous differ-
entiation), the other two cases were mucinous cysta-
denocarcinoma in 1 and papillary cystic carcinoma in
1. The remaining seven malignancies comprised
cholangiocarcinoma in three, neuroendocrine tumour
in three (islet cell carcinoma paraganglioma in one),
and colonic adenocarcinoma invading the pancreas in
one. Tumours were well differentiated in 7 patients,
moderately in 13, poorly in 15, undifferentiated in
1 and unknown in 7. Retropancreatic invasion was
observed in 31 cases (72%), lymph node invasion in
27 (62.8%), documented peri-neural invasion in 27
(62.8%) and microvascular invasion in 16 (37.2%).
Resection margins were R0 in 21 cases, R1 in 14
because of microscopic invasion of retropancreatic
margin in 11 (here retropancreatic free margin
B/1 mm was considered as R1), pancreatic cut section
in 1 and both in 2, R2 in 1 (macroscopic incomplete
retropancreatic clearance) and was not clearly docu-
mented Rx in 7.
Pathological examination of resected vessels
showed venous wall invasion in 13 cases (30%), 1 of
whom had associated arterial wall invasion. Ninteen
retropancreatic invasions were considered as perivas-
cular invasion without extension to vessel wall.
Information about vascular invasion was not available
in three resected specimens.
Adjuvant therapy was given to 10 patients; 8 had
combined radiochemotherapy, and 2 had either radio-
therapy or chemotherapy alone because of lymph
node invasion or non-R0 resection, other patients
were not fit for adjuvant treatment.
At the study end point, 44 patients were followed,
survival analysis was considered only for patients with
malignancies (n/43). Two patients operated for
pancreatic mass were found to have benign lesions
and were thus excluded from survival analysis, the
first was lost to follow-up and the second died 8 years
after surgery. Of the 43 patients with cancer,
30 (69.8%) had documented tumour recurrence:
11 loco-regional, 14 metastases and 5 had both.
Only 14 patients had treatment of their recurrence:
3 received combined radiochemotherapy, 6 had che-
motherapy alone, 4 had radiotherapy alone and 1 had
percutaneous alcoholization of a liver metastasis. The
other 16 patients had symptomatic treatment. DFS at
1, 2 and 3 years was 36.0%, 15.0% and 12.0%,
respectively (Figure 1). Median DFS length was
8.7 months (95% CI: 7.2; 10.2). Univariate analysis
for overall DFS (Table I) showed that tumour
localization, retropancreatic invasion and R0 resection
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Figure 1. Overall disease-free survival.
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(p valuesB/0.05) were explanatory variables. Inferior
vena cava (IVC) and renal vein (RV) resection, done
in one case each, were interesting variables (p/0.03
and 0.08, respectively) but not included in the final
model because each were done in only one patient.
Multivariate analysis for overall DFS final model
included (odds ratio; p value): tumour localization
(5.6;B/0.0001) (Figure 2), tumour stage (1.4; 0.03),
neoadjuvant treatment (3.1; 0.08). These variables
were also found at 1 and 3 years (although less
significant). None of the other significant variables
at the univariate level could remain in the multivariate
model.
Of these 43 cancer patients, 12 patients (27.9%)
were living and 31 died (1 postoperatively, 27 because
of disease recurrence and 3 of intercurrent disease).
The overall survival rate at 1, 2 and 3 years was
56.6%, 28.9% and 19.2%, respectively (Figure 3).
The median survival was 14.2 months (95% CI: 9.8;
18.6).
Univariate analysis for overall survival (Table I)
revealed that tumour localization, tumour stage and
recurrence were explanatory variables (pB/0.05).
Multivariate analysis for the overall survival final
model included the following variables (odds ratio;
p value): tumour localization (2.7; 0.02) (Figure 4),
tumour stage (1.4; 0.02), neoadjuvant treatment
Table I. Overall survival and disease-free survival (DFS) explicative variables and at 12 and 36 months follow-up (non-significant at 0.05
level).
Parameter
Overall
survival
Overall
DFS
12-month
survival
12-month
DFS
36-month
survival
36-month
DFS
Institution NS NS NS NS NS NS
Sex NS NS NS 0.024 NS NS
Tumour localization (HOP/other) 0.005 0.001 0.04 0.001 0.005 0.001
Neoadjuvant treatment NS NS NS NS NS NS
Intervention (PD/other) NS NS NS NS NS NS
Pylorus preservation NS NS NS NS NS NS
PV resection NS NS NS NS NS 0.06
SMV resection NS NS NS NS NS NS
SV resection NS NS NS NS NS NS
IVC resection NS 0.03 NS NS NS 0.04
Renal vein resection NS 0.08 NS 0.08 NS 0.008
Histology (ADK/other) NS NS NS NS NS NS
Tumour size (cm) NS NS NS NS NS NS
Tumour differentiation (good/other) NS NS NS NS NS NS
Node status (///) NS NS 0.1 NS NS NS
Vascular status (///) NS NS NS NS NS NS
Retropancreatic invasion 0.1 0.037 NS 0.033 NS 0.057
R0/R12 NS 0.048 NS 0.128 NS 0.048
Tumour stage 0.05 NS 0.02 0.02 0.02 0.08
Neoadjuvant treatment NS NS NS NS NS NS
Adjuvant treatment NS NS NS NS NS NS
Recurrence (local and metastatic) 0.01 NS 0.01 NS 0.04 NS
Local recurrence 0.001 NS 0.005 NS 0.03 NS
Metastatic recurrence NS NS NS NS NS NS
Venous resection NS NS NS 0.046 NS NS
Arterial resection NS NS NS NS NS NS
Arterial and venous resections NS NS NS NS NS NS
NS, not significant; HOP, head of pancreas; PD, pancreatico-duodenectomy; PV, portal vein; SMV, superior mesenteric vein; SV, splenic
vein; IVC, inferior vena cava; ADK, adenocarcinoma.
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Figure 2. Disease-free survival according to tumour localization:
head of pancreas versus other sites.
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(3.2; 0.09), tumour recurrence (3.3; 0.03). These
variables were also found at 1 and 3 years (although
less significant) (Table II).
Discussion
The preoperative diagnosis of vascular invasion in the
presence of pancreatic carcinoma is difficult to
determine and is usually based on imaging. Nowa-
days, coeliomesenteric angiography [9,11] has been
abandoned and replaced by non-invasive imaging
procedures such as triphasic helical CT scan, mag-
netic resonance imaging (MRI), Doppler ultrasound
and endosonography explorations [1214]. Indeed,
imaging procedures such as MRI and three-dimen-
sional CT allow the study of perivascular tissues with
complete assessment of resectability of pancreatic
carcinoma [1517].
In our strategy, segmental venous resection was
adopted systematically in the presence of tight adhe-
sions without concern as to their nature (malignant or
not) as long as the resection was considered macro-
scopically complete. This deliberated strategy was
adopted to avoid uncontrollable vascular injuries
during dissection. Venous resection was done en
monobloc with the pancreas as the final step of
resection to shorten the clamping time; associated
SMA clamping was not necessary. A direct end-to-
end suture is usually possible and the need for venous
graft is rare [18,19] but is usually recommended for
resection of /3 cm. This can be done using the long
saphenous vein [20] or the internal jugular vein [7] or
the superficial femoral vein harvested at mid-thigh
level under its confluence with the deep femoral vein,
as in one of our cases. The use of cryopreserved
vessels is another option for vascular reconstruction,
especially for arterial reconstruction when direct
anastomosis is not feasible [21].
Our series shows other uncommon types of vascular
resections: one patient had a wedge resection of the
IVC; 9 years later he is alive and disease-free. Another
patient had a ‘necessity’ resection of a RHA arising
from the SMA with a transtumoral crossing; 4 years
later he is alive and disease-free. As previously
reported, arterial resection could be considered
when carcinoma-free resection margin is fulfilled in
carefully selected cases [22].
Despite progress in imaging techniques, the nature
of radiological vascular involvement is still difficult to
60
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Figure 4. Survival according to tumour localization: head of
pancreas versus other sites.
Table II. Multivariate analysis for explanatory variables of disease-free survival (DFS) and overall survival.
DFS Overall survival
Parameter Odds ratio p value Odds ratio p value
Tumour localization (head of pancreas vs other) 5.6 B/0.0001 2.7 0.02
Tumour stage 1.4 0.03 1.4 0.02
Neoadjuvant treatment 3.1 0.08 3.2 0.09
Tumour recurrence   3.3 0.03
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Table III. Reported results of pancreatectomy along with vascular resections from different centres.
Authors Year No. of cases VR AR
Histological vascular
invasion (%)
Morbidity
rate (%)
Mortality
rate (%)
Median
survival (months)
Tashiro et al. [38] 1991 27 27 2 25.9 8.4 NA
Ishikawa et al. [9] 1992 31 85.7 5.7 9
Allema et al. [6] 1994 20 20 0 50 63 15 8
Takahashi et al. [25] 1994 79 63 16 61 16.4 14 (curative);
6 (non-curative)
Nakao et al. [11] 1995 89 49.4 8 NA
Fuhrman et al. [7] 1996 23 23 0 77.8
(7/9 examined specimen) 30 4 NA
Harrison et al. [18] 1996 58 58 0 NA Surgical
re-intervention/12
5 13
Roder et al. [30] 1996 31 31 0 61.3 41.9 0 8
Ogata et al. [39] 1997 107 103 21 23.1 5,6
Leach et al. [40] 1998 31 31 0 72
(13/18 examined specimen) NA 0 22
Shibata et al. [5] 2001 28 28 0 86 32 4 6.820.6
Sasson et al. [41] 2002 25 16 9 NA 38 1.7 NA
Kawada et al. [23] 2002 28 28 0 75 46 4 NA
Aramaki et al. [42] 2003 22 22 1 63.6 9.1 4.5 NA
Zhou et al. [28] 2005 32 32 0 62.5 31.25 NA NA
Present study 45
(43 cancer) 43 6 30 (40/43
examined)
24 (11 surgical
complications)
2.2 14.2
VR, vein resection; AR, artery resection; NA, not available.
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determine. In many instances, a perivascular inflam-
matory process may have the appearance of true
vascular invasion on imaging. Indeed, pathological
examination of resected vessels shows that the rate of
true vessel wall invasion is variable; according to
reported studies it varies from 21% to 86% [6,7,23].
In our series true vessel wall involvement was ob-
served in 30% of cases and only one of six resected
arteries was involved (17%). However, 19 other
patients had retropancreatic and perivascular invasion
which, retrospectively, justified vascular resection as it
allowed complete tumour clearance [24]. Neverthe-
less, the relatively high incidence of R1 resection is
explained by the inclusion in this group of all retro-
pancreatic invasion with a free margin of B/1 mm.
However, this group was not associated with worse
prognosis according to multivariate analysis. Another
argument for venous resection is the fact that, as
shown in our study and other reports, venous resec-
tion is done according to the pre- and per-operative
evaluation and not according to an objective docu-
mented pathology [11,25].
In our series, the survival of patients with and
without histologically documented vascular invasion
was not statistically different. These observations were
similar to the previously reported data [6,7,18], where
the survival of patients with or without histologically
invaded vessels was not statistically different. For
these reasons vascular resectability should be evalu-
ated clinically during operative exploration [26] and
venous involvement on preoperative examination
should be considered as the reflection of the anato-
mical barrier for tumour resection but not as an
absolute carcinological contraindication (our barrier
for resectability is venous involvement of /50% of
vascular circumference on angio-CT scan).
The attitude of centres regarding venous involve-
ment varies, but it clearly appears that elective
resection of a localized segment of the superior
mesenteric vein (SMV) or the portal vein (PV),
when all the criteria for carcinological resectability
are fulfilled, does not significantly increase the mor-
bidity or mortality, is associated with fair results and
the presence of venous invasion is not associated with
poor prognosis [18,25,2729]. Other authors corre-
lated the depth of vessel wall invasion with survival
[6,30]. Our study shows that venous and arterial
resections do not increase perioperative mortality and
morbidity with a 3-year overall survival rate of 19.2%.
The rationale of venous resection is now admitted
in centres of expertise, Table III reports results
of pancreatectomies along with vascular resections
from different centres, showing a rate of vascular
invasion from 25.9% to 77.8% of examined speci-
mens, a morbidity rate of 23.163%, a mortality rate
ranging from 0 to 16.4% and a median survival range
of 822 months.
Several studies evaluated the independent risk
factors influencing survival after pancreatectomies.
According to multivariate analysis (Table IV) lymph
node invasion was the most commonly found, fol-
lowed by surgical margin invasion, then poor tumour
differentiation, large tumour size, blood vessel inva-
sion and blood transfusion [3136], while favourable
prognostic factors of good outcome were radical
resection and adjuvant radiochemotherapy [34,37].
Our multivariate analysis showed only three explana-
tory factors that affected DFS: tumour localization
outside the pancreatic head, tumour stage and
neoadjuvant treatment. These same variables as well
as tumour recurrence were found for survival analysis.
Vessel wall invasion did not affect either survival or
DFS. These analyses also show that neoadjuvant
treatment is associated with worse prognosis and
does not seem beneficial in this retrospective analysis
where neoadjuvant treatments were done in different
heterogenous situations that do not allow definite
conclusions and the p value was not statistically
significant in the multivariate model. Because of
worse prognosis for tumour located in the body and
tail of the pancreas, these patients might benefit from
systematic adjuvant therapy.
Conclusion
Vascular resections associated with pancreatectomies
do not increase perioperative mortality and morbidity
and should be considered as part of the surgical
strategy. These resections should be planned and
decided as soon as possible during the preoperative
evaluation. During surgery, if it is difficult to deter-
mine whether the tight adhesions with the vessel wall
are only due to inflammation or secondary to tumour
extension, in these situations we perform a controlled
segmental venous resection to avoid uncontrollable
vascular injuries. Nevertheless, in all cases vascular
resections are only performed when all oncological
criteria for resectability are fulfilled and to obtain
cancer-free surgical margins.
Our results showed that tumour localization, tu-
mour stage, neoadjuvant treatment and tumour
recurrence are explanatory variables of survival.
Table IV. Survival independent factors according to multivariate
analyses.
Variable [refs] Hazard ratio p value
Positive lymph node [3136] 1.513.31 0.080.0065
Positive surgical margin
[3436]
1.3 0.28
Poor T differentiation [32,35] 1.82 0.0062
Tumour size /2.5 cm [32,36] 2.77 0.0011
Blood vessel invasion [31,33] 1.612.19 0.0330.025
Blood transfusion [32] 2.13 0.015
Intrapancreatic perineural
invasion [33]
1.83 0.0018
Radical resection [37] 0.51 0.002
/Adjuvant therapy [34] 0.26 B/ 0.001
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Tumour localization, tumour stage and neoadjuvant
treatment were explanatory variables for DFS,
whereas the type and extent of vascular resection as
well as vessel wall invasion do not affect survival and
DFS.
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